SLFN12 and myeloid sarcoma: These regions may influence disease etiology and shed light on risk factors for MS [24] as SLFN12 is a biologically plausible gene of interest for MS since there is substantial evidence from clinical observations and genetic studies that MS pathology is driven by T cells and that IFN beta type I, which induce expression of SLFN genes is an authorized treatment for MS [46].